Abatacept biosimilar - Sunshine Guojian Pharmaceutical

Drug Profile

Abatacept biosimilar - Sunshine Guojian Pharmaceutical

Alternative Names: CTLA4-Ig Fusion protein - Sunshine Guojian Pharmaceutical; Lei Ning; Recombinant human CTLA4-Ig Fusion protein -Sunshine Guojian Pharmaceutical

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai CP Guojian Pharmaceutical
  • Class Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins
  • Mechanism of Action CD80 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 24 Mar 2014 No development reported - Preregistration for Rheumatoid arthritis in China (Parenteral)
  • 01 Dec 2011 Preregistration for Rheumatoid arthritis in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top